Editorial by US Food and Drug Administration Attorney Fails to Address Core and Ongoing Issues Seen With Vasopressin Market

Anesth Analg. 2019 Apr;128(4):e55-e56. doi: 10.1213/ANE.0000000000004042.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Drugs, Generic*
  • Hospital Costs
  • Humans
  • Lawyers*
  • United States
  • United States Food and Drug Administration
  • Vasopressins

Substances

  • Drugs, Generic
  • Vasopressins